Guidelines for the Management of Secondary Hypogammaglobulinemia in Multiple Sclerosis Patients on Anti-CD20 Monoclonal Antibody Therapy
DOI:
https://doi.org/10.20344/amp.24365Keywords:
Agammaglobulinemia/chemically induced, Antibodies, Monoclonal, Humanized/adverse effects, Immunologic Factors/adverse effects, Infections/ prevention and control, Multiple Sclerosis/drug therapyAbstract
Hypogammaglobulinemia is a common laboratory complication in patients with multiple sclerosis treated with anti-CD20 monoclonal antibodies, and it may be associated with an increased risk of infections. This guideline, developed by the Cerebrospinal Fluid Study and Research Unit of Unidade Local de Saúde São João, proposes a structured approach for the assessment and management of this condition. It outlines strategies for infection risk mitigation both before and during therapy, as well as the indications for initiating immunoglobulin replacement therapy when appropriate. The aim is to support clinical decision-making by promoting a safe, individualized, and patient-centered intervention.
Downloads
References
Oksbjerg NR, Nielsen SD, Blinkenberg M, Magyari M, Sellebjerg F. Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases. Mult Scler Relat Disord. 2021;52:102988. DOI: https://doi.org/10.1016/j.msard.2021.102988
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New Engl J Med. 2016;376:221-34. DOI: https://doi.org/10.1056/NEJMoa1601277
Baker D, Pryce G, James LK, Marta M, Schmierer K. The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Mult Scler Relat Disord. 2020;44:102279. DOI: https://doi.org/10.1016/j.msard.2020.102279
European Medicines Agency. Ocrevus EPAR Product Information. [consultado 2024 jun 17]. Disponível em: https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383:546-57. DOI: https://doi.org/10.1056/NEJMoa1917246
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376:209-20. DOI: https://doi.org/10.1056/NEJMoa1606468
Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, et al. Ublituximab versus teriflunomide in relapsing multiple sclerosis. N Engl J Med. 2022;387:704-14. DOI: https://doi.org/10.1056/NEJMoa2201904
Sempere AP, Berenguer-Ruiz L, Borrego-Soriano I, Burgos-San Jose A, Concepcion-Aramendia L, Volar L, et al. Ocrelizumab in multiple sclerosis: a real-world study from Spain. Front Neurol. 2020;11:592304. DOI: https://doi.org/10.3389/fneur.2020.592304
Fernandez-Diaz E, Perez-Vicente JA, Villaverde-Gonzalez R, Berenguer-Ruiz L, Merlicco AC, Martinez-Navarro ML, et al. Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population. Ann Clin Transl Neurol. 2021;8:385-94. DOI: https://doi.org/10.1002/acn3.51282
Fernandes AA, Neves AL, Ferro D, Seabra M, Mendonça T, Soares dos Reis R, et al. Clinical and analytical monitoring of patients with multiple sclerosis on anti-CD20 therapeutics: a real-world safety profile study. Front Neurol. 2024;15:1500763. DOI: https://doi.org/10.3389/fneur.2024.1500763
Alvarez E, Longbrake EE, Rammohan KW, Stankiewicz J, Hersh CM. Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: pathogenesis, risk of infection, and disease management. Mult Scler Relat Disord. 2023;79:105009. DOI: https://doi.org/10.1016/j.msard.2023.105009
Otani IM, Lehman HK, Jongco AM, Tsao LR, Azar AE, Tarrant TK, et al. Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a work group report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees. J Allergy Clin Immunol. 2022;149:1525-60. DOI: https://doi.org/10.1016/j.jaci.2022.01.025
Jolles S, Michallet M, Agostini C, Albert MH, Edgar D, Ria R, et al. Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus. Eur J Haematol. 2021;106:439-49. DOI: https://doi.org/10.1111/ejh.13580
Smith TE, Kister I. Infection mitigation strategies for multiple sclerosis patients on oral and monoclonal disease-modifying therapies. Curr Neurol Neurosci Rep. 2021;21:36. DOI: https://doi.org/10.1007/s11910-021-01117-y
Zingaropoli MA, Pasculli P, Iannetta M, Perri V, Tartaglia M, Crisafulli G, et al. Infectious risk in multiple sclerosis patients treated with disease-modifying therapies: a three-year observational cohort study. Mult Scler J Exp Transl Clin. 2022;8:20552173211065731. DOI: https://doi.org/10.1177/20552173211065731
Papeix C, Donze C, Lebrun-Frénay C. Infections and multiple sclerosis: recommendations from the French Multiple Sclerosis Society. Rev Neurol. 2021;177:980-94. DOI: https://doi.org/10.1016/j.neurol.2021.04.011
Direção-Geral da Saúde. Norma 013/2024 de 19/12/2024: atualização da estratégia de vacinação pneumocócica – programa nacional de vacinação e grupos de risco. Lisboa: DGS; 2024.
Hwang JP, Feld JJ, Hammond SP, Wang SH, Alston-Johnson DE, Cryer DR, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol. 2020;38:3698-715. DOI: https://doi.org/10.1200/JCO.20.01757
Associação Portuguesa de Urologia. Prevenção da infeção urinária recorrente. 2018. [consultado 2025 out 02]. Disponível em: https://apurologia.pt/wp-content/uploads/2018/10/prev-infec-urin-recorr.pdf.
Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev. 2013;27:171-8. DOI: https://doi.org/10.1016/j.tmrv.2013.05.004
Giralt S, Jolles S, Kerre T, Lazarus HM, Mustafa SS, Papanicolaou GA, et al. Recommendations for management of secondary antibody deficiency in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2023;23:719-32. DOI: https://doi.org/10.1016/j.clml.2023.05.008
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Acta Médica Portuguesa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.
